GTEC Building the Cities China (literally) Demands
What I like about Lotus is the fact that they have FIFTEEN drug stores in Beijing AND they are adding wellness centers to some of these. In addition they are doing research and development for new pharmaceuticals.
This is not your normal pharmaceutical approach in the west. This is incredibly good business management. They are generating revenue from fifteen established pharmacies in Beijing — a huge city with 12.8 million people now and expected to hit over 15 million by 2008. That’s an additional 2.2 million people to build on the foot traffic Lotus pharmacies are already experiencing. By building on their basic pharmacy concept with the addition of wellness centers, Lotus is fully exploiting their basic clientele.
But this is what is so amazing — they are using that revenue to develop new drugs. They are focused in some incredibly widespread diseases like hypertension, infectious disease injections and circulatory diseases. They are not looking at small unique categories of disease but at the blockbuster widespread diseases.
This business plan has virtually no flaws — establish your pharmacies in one of the largest cities in the world that is going at a phenomenal pace, enhance your offerings to a wellness center and take that revenue and develop blockbuster drugs for some of the most common diseases.
Genesis Technology Group’s Lotus Pharmaceuticals released its catalog of drugs that projects sales exceeding $50 million last week, and what is so amazing is the fact that these drugs are directed toward the most common diseases in the world.
Lotus markets both drugs developed through their own Research and Development program and licensed drugs that have proved successful internationally.
Drugs developed by Lotus presently on the Chinese market:
1. Valsartan Capsules for the treatment of medium and critical
degree high blood pressure and coronary heart disease, with annual
sales estimated at $12 million.
2. Levofloxacin lactate for injection for the treatment of infectious
diseases, with annual sales estimated at $8 million.
3. Brimonidine tartrate eye drops for the treatment of glaucoma and
ocular hypertension, with annual sales estimated at $4 million.
4. Nicergoline for injection for the treatment of cerebrovascular
disease sequela and other peripheral circulatory disorders, with
annual sales estimated at $4 million.
Drugs under license to Lotus presently on the Chinese market:
1. Sodium Aescinate for injection for the treatment of cerebral oedema
caused by different diseases, trauma, swelling caused by operations
and venous return disturbance, with annual sales estimated at
$8 million.
2. Gatifioxacin for injection for the treatment of various infectious
diseases, with annual sales estimated at $6 million.
Drugs under development by Lotus not yet on the Chinese market:
1. Valsartan Dropping Pills, a patented medicine exclusively produced
by Lotus for the treatment of medium and critical degree
essential hypertension, with forecasted annual sales of
$20 million.
Lotus has fifteen pharmacies in Beijing and they are incorporating wellness centers into those stores now with gymnasiums and wellness spas. Their business plan is designed to treat the masses … and at 15 million citizens, that’s a lot of disease.
Genesis Technology Group, Inc. Boca Corporate Plaza
7900 Glades Road, Suite 420
Boca Raton, FL 33434
Phone: (561) 988-9880
Fax: (561) 988-9890
Email: General Information: info@genesis-china.net
Investor relations: clinton@genesis-china.net
Disclosure: Pentony Enterprises LLC has been compensated $3,600 and 265,000 restricted shares directly from the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.
Forward Looking Statement: Certain sections of this report may contains forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, aircraft production, deliveries and backlog stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors, including, without limitation:
General and international political and economic conditions; All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
